Closed
The Marked Chart Wire · Health
Mineralys Therapeutics
Mineralys Therapeutics said lorundrostat lowered systolic blood pressure by 17.8 mmHg at week 48 in a phase 3 trial extension. About 56 percent of patients reached levels below 130 mmHg.
New to this? Read: Reading a stock chart
FDA Approval
The FDA has approved daraxonrasib from Revolution Medicines for the treatment of pancreatic cancer.
Evaxion
The biotech firm disclosed new Phase 2 findings for its personalized vaccine, EVX-01. The data indicated robust immune reactions and validated its AI-Immunology platform.
Novartis
Novartis is said to be discontinuing a heart medication developed with Ionis following a late-stage clinical trial failure.
J&J Psoriasis Drug
Johnson & Johnson announced positive results from a late-stage trial of its oral medication for plaque psoriasis and psoriatic arthritis.
Wegovy
Novo Nordisk presented real-world results showing that semaglutide 2.4 mg improved liver markers, body weight, and glucose levels in adults with MASH. The drug outperformed resmetirom in reducing AST and other cardiometabolic indicators.
Measles
American health officials report over 5,000 confirmed measles cases, the most recorded in three and a half decades.
Fast headlines, summarized. Not verified and not advice. Check the full story before you act.